Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm or Refractory Malignant Neoplasm
and you are
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Provided treatments

  • Drug: Everolimus
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Drug: Vandetanib
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01582191. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 174 volunteers for the current phase.
Official trial title:
A Phase 1 Trial of Vandetanib (a Multi-Kinase Inhibitor of EGFR, VEGFR, and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer